Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia

News
Video

This video examines frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia, including considerations for when chemotherapy or ibrutinib might be more appropriate.

In this video, Susan O’Brien, MD, of the University of California Irvine Medical Center, discusses frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia (CLL). In order to provide personalized therapy for patients, certain factors may determine whether chemotherapy or ibrutinib would be the more appropriate option.

Dr. O’Brien also discusses novel agents approved as second-line therapies for CLL and side effect profiles physicians should consider when recommending treatment.

Related Videos
Related Content
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML

April 12th 2024
Article

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML

March 29th 2024
Article

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.

No Major Racial Disparities Reported in Allogeneic Transplant Outcomes

March 20th 2024
Article

Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

FDA Grants Accelerated Approval to Ponatinib Combo in Ph+ ALL

March 19th 2024
Article

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.